Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anish Konkar is active.

Publication


Featured researches published by Anish Konkar.


Science Translational Medicine | 2013

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Brian Finan; Tao Ma; Nickki Ottaway; Timo D. Müller; Kirk M. Habegger; Kristy M. Heppner; Henriette Kirchner; Jenna Holland; Jazzminn Hembree; Christine Raver; Sarah Kathleen Haas Lockie; David L. Smiley; Vasily Gelfanov; Bin Yang; Susanna M. Hofmann; Dennis Bruemmer; Daniel J. Drucker; Paul T. Pfluger; Diego Perez-Tilve; Jaswant Gidda; Louis Vignati; Lianshan Zhang; Jonathan Hauptman; Michele Lau; Mathieu Brecheisen; Sabine Uhles; William Riboulet; Emmanuelle Hainaut; Elena Sebokova; Karin Conde-Knape

Compared to best-in-class GLP-1 mono-agonists, unimolecular co-agonists of GLP-1 and GIP with optimized pharmacokinetics enhance glycemic and metabolic benefits in mammals. “Twincretins”: Two Is Better than One Despite obesity-linked diabetes approaching worldwide epidemic proportions and the growing recognition of it as a global health challenge, safe and effective medicines have remained largely elusive. Pharmacological options targeting multiple obesity and diabetes signaling pathways offer greater therapeutic potential compared to molecules targeting a single pathway. Finan et al. now report the discovery, characterization, and translational efficacy of a single molecule that acts equally on the receptors for the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). In rodent models of obesity and diabetes, this dual incretin co-agonist more effectively lowered body fat and corrected hyperglycemia than selective mono-agonists for the GLP-1 and GIP receptors. An enhanced insulinotropic effect translated from rodents to monkeys and humans, with substantially improved levels of glycosylated hemoglobin A1c (HbA1c) in humans with type 2 diabetes. The dual incretin was engineered with selective chemical modifications to enhance pharmacokinetics. This, in combination with its inherent mixed agonism, lowered the drug dose and ameliorated the dose-limiting nausea that has plagued selective GLP-1 therapies. These dual incretin co-agonists signify a new direction for unimolecular combination therapy and represent a new class of drug candidates for the treatment of metabolic diseases. We report the discovery and translational therapeutic efficacy of a peptide with potent, balanced co-agonism at both of the receptors for the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This unimolecular dual incretin is derived from an intermixed sequence of GLP-1 and GIP, and demonstrated enhanced antihyperglycemic and insulinotropic efficacy relative to selective GLP-1 agonists. Notably, this superior efficacy translated across rodent models of obesity and diabetes, including db/db mice and ZDF rats, to primates (cynomolgus monkeys and humans). Furthermore, this co-agonist exhibited synergism in reducing fat mass in obese rodents, whereas a selective GIP agonist demonstrated negligible weight-lowering efficacy. The unimolecular dual incretins corrected two causal mechanisms of diabesity, adiposity-induced insulin resistance and pancreatic insulin deficiency, more effectively than did selective mono-agonists. The duration of action of the unimolecular dual incretins was refined through site-specific lipidation or PEGylation to support less frequent administration. These peptides provide comparable pharmacology to the native peptides and enhanced efficacy relative to similarly modified selective GLP-1 agonists. The pharmacokinetic enhancement lessened peak drug exposure and, in combination with less dependence on GLP-1–mediated pharmacology, avoided the adverse gastrointestinal effects that typify selective GLP-1–based agonists. This discovery and validation of a balanced and high-potency dual incretin agonist enables a more physiological approach to management of diseases associated with impaired glucose tolerance.


Nature Medicine | 2015

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

Brian Finan; Bin Yang; Nickki Ottaway; David L. Smiley; Tao Ma; Christoffer Clemmensen; Joe Chabenne; Lianshan Zhang; Kirk M. Habegger; Katrin Fischer; Jonathan E. Campbell; Darleen A. Sandoval; Randy J. Seeley; Konrad Bleicher; Sabine Uhles; William Riboulet; Jürgen Funk; Cornelia Hertel; Sara Belli; Elena Sebokova; Karin Conde-Knape; Anish Konkar; Daniel J. Drucker; Vasily Gelfanov; Paul T. Pfluger; Timo D. Müller; Diego Perez-Tilve; Richard D. DiMarchi; Matthias H. Tschöp

We report the discovery of a new monomeric peptide that reduces body weight and diabetic complications in rodent models of obesity by acting as an agonist at three key metabolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. This triple agonist demonstrates supraphysiological potency and equally aligned constituent activities at each receptor, all without cross-reactivity at other related receptors. Such balanced unimolecular triple agonism proved superior to any existing dual coagonists and best-in-class monoagonists to reduce body weight, enhance glycemic control and reverse hepatic steatosis in relevant rodent models. Various loss-of-function models, including genetic knockout, pharmacological blockade and selective chemical knockout, confirmed contributions of each constituent activity in vivo. We demonstrate that these individual constituent activities harmonize to govern the overall metabolic efficacy, which predominantly results from synergistic glucagon action to increase energy expenditure, GLP-1 action to reduce caloric intake and improve glucose control, and GIP action to potentiate the incretin effect and buffer against the diabetogenic effect of inherent glucagon activity. These preclinical studies suggest that, so far, this unimolecular, polypharmaceutical strategy has potential to be the most effective pharmacological approach to reversing obesity and related metabolic disorders.


Diabetes | 2013

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

Kirk M. Habegger; Kerstin Stemmer; Christine C. Cheng; Timo D. Müller; Kristy M. Heppner; Nickki Ottaway; Jenna Holland; Jazzminn Hembree; David L. Smiley; Vasily Gelfanov; Radha Krishna; Ayman M. Arafat; Anish Konkar; Sara Belli; Martin Kapps; Stephen C. Woods; Susanna M. Hofmann; David A. D’Alessio; Paul T. Pfluger; Diego Perez-Tilve; Randy J. Seeley; Morichika Konishi; Nobuyujki Itoh; Alexei Kharitonenkov; Joachim Spranger; Richard D. DiMarchi; Matthias H. Tschöp

Glucagon, an essential regulator of glucose homeostasis, also modulates lipid metabolism and promotes weight loss, as reflected by the wasting observed in glucagonoma patients. Recently, coagonist peptides that include glucagon agonism have emerged as promising therapeutic candidates for the treatment of obesity and diabetes. We developed a novel stable and soluble glucagon receptor (GcgR) agonist, which allowed for in vivo dissection of glucagon action. As expected, chronic GcgR agonism in mice resulted in hyperglycemia and lower body fat and plasma cholesterol. Notably, GcgR activation also raised hepatic expression and circulating levels of fibroblast growth factor 21 (FGF21). This effect was retained in isolated primary hepatocytes from wild-type (WT) mice, but not GcgR knockout mice. We confirmed this link in healthy human volunteers, where injection of natural glucagon increased plasma FGF21 within hours. Functional relevance was evidenced in mice with genetic deletion of FGF21, where GcgR activation failed to induce the body weight loss and lipid metabolism changes observed in WT mice. Taken together, these data reveal for the first time that glucagon controls glucose, energy, and lipid metabolism at least in part via FGF21-dependent pathways.


Journal of Controlled Release | 2013

PK modulation of haptenylated peptides via non-covalent antibody complexation

Eike Hoffmann; Anish Konkar; Sebastian Dziadek; Hans-Peter Josel; Karin Conde-Knape; Holger Kropp; Lothar Kling; Kay Stubenrauch; Stefan Dengl; Ulrich Brinkmann

We applied noncovalent complexes of digoxigenin (Dig) binding antibodies with digoxigeninylated peptide derivatives to modulate their pharmacokinetic properties. A peptide derivative which activates the Y2R receptor was selectively mono-digoxigeninylated by reacting a NHS-Dig derivative with an ε-amino group of lysine 2. This position tolerates modifications without destroying receptor binding and functionality of the peptide. Dig-peptide derivatives can be loaded onto Dig-binding IgGs in a simple and robust reaction, thereby generating peptide-IgG complexes in a defined two to one molar ratio. This indicates that each antibody arm becomes occupied by one haptenylated peptide. In vitro receptor binding and signaling assays showed that Dig-peptides as well as the peptide-antibody complexes retain better potency than the corresponding pegylated peptides. In vivo analyses revealed prolonged serum half-life of antibody-complexed peptides compared to unmodified peptides. Thus, complexes are of sufficient stability for PK modulation. We observed more prolonged weight reduction in a murine diet-induced obesity (DIO) model with antibody-complexed peptides compared to unmodified peptides. We conclude that antibody-hapten complexation can be applied to modulate the PK of haptenylated peptides and in consequence improve the therapeutic efficacy of therapeutic peptides.


Bioconjugate Chemistry | 2013

Preparation and characterization of albumin conjugates of a truncated peptide YY analogue for half-life extension.

George Ehrlich; Hanspeter Michel; Theresa Truitt; William Riboulet; Petar Pop-Damkov; Petra Goelzer; Dominik Hainzl; Farooq Qureshi; Barbara Lueckel; Waleed Danho; Karin Conde-Knape; Anish Konkar

Recombinant human serum albumin (HSA) conjugates of a 15-amino-acid truncated peptide YY (PYY) analogue were prepared using three heterobifunctional linkers [succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (SMCC), 6-maleimidohexanoic acid N-hydroxysuccinimide ester (MHS), and N-[γ-maleimidobutyryloxy]sulfosuccinimide ester (GMBS)] in 2 synthetic steps involving (1) reaction of succinimidyl ester on linker with ε-amine of Lys2 on the peptide and (2) reaction of maleimide on peptide linker with free thiol of Cysteine 34 (Cys34) on albumin. In-process controls using ESI LC-MS were used to follow reactions and identify reaction products. Proteolytic digests of the conjugate revealed that peptide conjugation occurs at Cys34 on HSA. Conjugates were assayed in cell-based assays to determine potency at the human Y2-receptor, and selectivity at the human Y1-, Y4-, and Y5-receptors using a calcium flux assay. All three conjugates assayed were selective agonists of the Y2-receptor, and displayed nanomolar potencies. MCC and MH conjugates were selected for acute PK/PD studies in DIO mice. Significant reduction in food intake was observed with the MH conjugate, which lasted for 24 h at the 10 mg (or 4 μmol)/kg dose. While the MCC conjugate exhibited greater potency in vitro, it was slightly less effective than the MH conjugate in vivo with respect to reduction in food intake. Both conjugates were significantly less active than the peptide coupled to a 30 kDa PEG. The observed T1/2 (8-9 h) for both conjugates was significantly lower than that observed for the PEGylated peptide (∼25 h). These results suggest that, as compared with the unmodified and PEGylated peptide, the extended circulation half-life of albumin conjugates is mediated through uptake and recirculation by FcRn, and allometric scaling methods are necessary to account for interspecies variation in pharmacokinetic properties.


Archive | 2006

Neuropeptide-2 receptor-agonists

Karin Conde-Knape; Waleed Danho; George Ehrlich; Nader Fotouhi; David C. Fry; Wajiha Khan; Anish Konkar; Cristina M. Rondinone; Joseph Swistok; Rebecca Taub; Jefferson Wright Tilley


Archive | 2009

Neuropeptide-2 receptor (y-2r) agonists and uses thereof

Karin Conde-Knape; Waleed Danho; George Ehrlich; Nader Fotouhi; David C. Fry; Wajiha Khan; Anish Konkar; Cristina M. Rondinone; Joseph Swistok; Rebecca Taub; Jefferson Wright Tilley


Drug Discovery Today: Therapeutic Strategies | 2007

Fatty acid modulators for the treatment of diabesity

Stanley Wertheimer; David Robert Bolin; Shawn David Erickson; Karin Conde-Knape; Charles Belunis; Anish Konkar; Rebecca Taub; Cristina M. Rondinone


Archive | 2012

New aryl-benzocycloalkyl amide derivatives

Johannes Aebi; Alfred Binggeli; Cornelia Hertel; Anish Konkar; Holger Kuehne; Bernd Kuhn; Hans P. Maerki; Haiyan Wang


Archive | 2014

LIPIDATED INCRETIN RECEPTOR LIGAND HUMAN IMMUNOGLOBULIN FC-REGION FUSION POLYPEPTIDES

Sara Belli; Konrad Bleicher; Richard D. Dimarchi; Eike Hoffmann; Eric Argirios Kitas; Anish Konkar

Collaboration


Dive into the Anish Konkar's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David L. Smiley

Indiana University Bloomington

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge